Background and Aims: Non-small cell lung cancer (NSCLC) is the most common cause of cancer death in the world.
Results: In the present research, PLGA/CAP1-siRNA nanoparticles were prepared and used to deliver CAP1-siRNA to A549 cells and down regulate CAP1 expression both in vitro and in vivo. The attractive performance of PLGA/CAP1-siRNA nanoparticles for delivering siRNA was confirmed by transwell assay, scratch assay and animal experiments.
Conclusion:
The results demonstrated that the multifunctional nanoparticles interfered with the expression of CAP1 and reduced NSCLC metastasis both in vitro and in vivo, suggesting that PLGA/CAP1-siRNA nanoparticles may become a new strategy of the treatment for metastasic NSCLC. European Society for Medical Oncology (ESMO) guideline suggests that screening for brain metastases (BM) with MRI might be useful in patients considering for curative therapy. While the prevalence of brain metastasis (BM) is known to be very low in patients with stage I squamous cell carcinoma, that of patients with adenocarcinoma is not well studied. In the present study, we aimed to evaluate the prevalence of brain metastasis across the stages and clinical factors associated with BM.
Methods: Patients who were diagnosed with lung adenocarcinoma at Samsung Medical Center in 2014 were retrospectively identified and reviewed comprehensively for TNM staging by 8th edition of AJCC. All brain metastasis were confirmed by gadolinium-enhanced magnetic resolution image and invasive nodal staging were performed in all patients with equivocal nodal metastasis in CT/PET. Background and Aims: The identification of EGFR mutation is very important for advanced NSCLC been diagnosed. The traditional method is gene analysis from biopsied tissue. The procedures for tissue biopsy are usually invasive. Liquid biopsy is less invasive and can identify circulating tumor DNA from patients' blood. However, the association between tissue biopsy and liquid biopsy for EGFR mutation in adenocarcinoma before treatment remains unclear. Our study aimed to evaluate the association between the results from liquid biopsy and tissue biopsy in advanced NSCLC patients before treatment. 
